Benzydamine inhibits osteoclast differentiation and bone resorption via down-regulation of interleukin-1β expression

• Main Authors: Han Saem Son (Author), Jiae Lee (Author), Hye In Lee (Author), Narae Kim (Author), You-Jin Jo (Author), Gong-Rak Lee (Author), Seong-Eun Hong (Author), Minjeong Kwon (Author), Nam Young Kim (Author), Hyun Jin Kim (Author), Jin Ha Park (Author), Soo Young Lee (Author), Woojin Jeong (Author)
• Format: Book
• Published: Elsevier, 2020-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Bone diseases such as osteoporosis and periodontitis are induced by excessive osteoclastic activity, which is closely associated with inflammation. Benzydamine (BA) has been used as a cytokine-suppressive or non-steroidal anti-inflammatory drug that inhibits the production of pro-inflammatory cytoki...